Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06541509
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-11
Brief Title:
Mechanisms of Semaglutide Therapy in Heart Failure Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Pilot Clinical Trial Investigating Underlying Mechanisms of Semaglutide Therapy in Heart Failure Patients
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SEMAHEART
Brief Summary:
Semaglutide is a glucagon-like peptide-1 GLP-1 receptor agonist primarily used for treatment of type-2 diabetes mellitus GLP-1 receptors are present on pancreatic islet β-cells δ-cells and α-cells Their stimulation increases insulin and somatostatin secretion and decreases glucagon secretion In addition GLP-1 receptor agonists appear to have multiple extrapancreatic actions which remain poorly defined In large clinical trials semaglutide improved the outcomes in obese patients patients with heart failure with preserved ejection fraction and decreased the heart failure hospitalizations in patients with type 2 diabetes The aim of the present study is to investigate the underlying mechanisms of the beneficial clinical effects of semaglutide in the setting of chronic heart failure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None